RT Journal Article
SR Electronic
T1 Sensitivity and specificity of prediction models based on gustatory disorders in diagnosing COVID-19 patients: a case-control study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.31.20118380
DO 10.1101/2020.05.31.20118380
A1 Adamczyk, Kamil
A1 Herman, Michał
A1 Frączek, Janusz
A1 Piec, Robert
A1 Szykuła-Piec, Barbara
A1 Zaczyński, Artur
A1 Wójtowicz, Rafał
A1 Bojanowski, Krzysztof
A1 Rusyan, Ewa
A1 Król, Zbigniew
A1 Wierzba, Waldemar
A1 Franek, Edward
YR 2020
UL http://medrxiv.org/content/early/2020/06/03/2020.05.31.20118380.abstract
AB Objective to quantitatively assess disturbances of sweet, sour and salty and bitter tastes in a group of young, asymptomatic or oligosymptomatic COVID-19 patients; establish a reliable, sensitive and specific test that can diagnose COVID-19 on the basis of taste disorders and publish the results according to STARD 2015 statement (Standards for Reporting Diagnostic Accuracy).Design case-control studySetting isolated rooms in the Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw (which had been transformed into an infectious hospital) and a dormitory in one of Warsaw universities.Participants 52 SARS-CoV-2 positive (51 men, mean age 21.7 years) and 36 negative students (34 men, mean age 20.8 years).Main outcome measures a gustatory function assessment (sweet, salty, sour and bitter taste), with flavour concentrations established previously in healthy subjects was conducted for all subjects. Each participant received one tasteless reference and nine flavour tablets with sucrose concentrations of 40, 80 and 106.4 mg/ml; NaCl at 13.5, 17 and 27 mg/ml; ascorbic acid at 6.25 and 12.5 mg/ml and grapefruit extract at 40 mg/ml.Results the only taste that was impaired significantly more frequently in COVID-19 patients was the sweet taste at the lowest flavour concentration (40 mg/ml, p = 0.002). Different screening and diagnostic models were constructed using the examined variables. The highest accuracy screening test consisted of the positive result of a three-question questionnaire (self-reported loss of taste, self-reported loss of smell, or fever within the last month (positive if at least one present) and/or ageusia of sweet taste at a sucrose concentration of 40 mg/ml. The sensitivity of the model was 94% with a specificity of 55%. The highest accuracy diagnostic test consisted of ageusia of sweet taste at a sucrose concentration of 106.4 mg/ml or/and ageusia of salty taste at an NaCl concentration of 13.5 or 17 mg/ml. The specificity of the test was found to be 100%, and the sensitivity was 34%.Conclusion as the most effective way of controlling the present pandemic involves testing the wider population for symptomatic, oligosymptomatic and asymptomatic carriers of SARSCoV-2 and isolating or hospitalising infected subjects, in the present study, an inexpensive, simple, fast and sensitive (94%) screening test that can be used for such a purpose is proposed. In addition, a specific (100%) diagnostic test that could be used to refer patients to quarantine in the case of limited availability of genetic or serological tests is proposed.Competing Interest StatementKamil Adamczyk, Michal Herman, Janusz Fraczek, Edward Franek and Artur Zaczynski: pending patent for a method for sreening of for increased risk of SARS-COV-2 infection, diagnostic test kit and implementing this method. Polish Patent Office No B.434028, Kamil Adamczyk, Michal Herman, Janusz Fraczek, and Artur Zaczynski: Pending patent for system and method for detecting taste disturbances among the population with a viral infection, in particular, SARS-CoV-2 infection".Polish Patent Office submission number P.433465Funding StatementNo external funds were provided for any aspect of study and manuscript preparation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Commission for Supervising Research on Humans and Animals, Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw, ul. Woloska 137, 02-507 Warsaw, Poland All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll available data are accesible in the manuscript.